No abstract available.

No abstract available.
Bronchopulmonary Sequestration*

No abstract available.
Pneumothorax, Artificial* ; Treatment Failure* ; Tuberculosis, Pulmonary*

No abstract available.
Biopsy*

BACKGROUND/AIMS: To compare efficacy and tolerability of rabeprazole (RAB) 10 mg versus omeprazole (OME) 20 mg in patients with duodenal ulcer. METHODS: This randomized, comparative, multicenter study was conducted at 10 centers in Korea, from February to September in 1999. Patients with active duodenal ulcer as proven by endoscopy were randomized to RAB (n=123) or OME (n=123) groups. One hundred-twenty-three patients received RAB 10 mg once daily, and 123 patients received OME 20 mg once daily for 2 or 4 weeks. Primary efficacy parameter was complete healing by endoscopy and secondary parameter was the improvement in the severity of clinical symptoms after the therapy. RESULTS: After 2 weeks, complete healing was achieved in 81.7% (85/104) of patients given RAB 10mg and in 81.1% (77/95) of patients given OME 20 mg (p=0.902). After 4 weeks, complete healing was documented in 97.1% (101/104) of patients given RAB 10 mg and in 93.7% (89/95) of patients given OME 20 mg (p=0.315). The percentages of patients resolved daytime pain and night-time pain at Day 4 were 87.5% and 90.1% in RAB group and 79.0% and 80.5% in OME group (p=0.138 and p=0.087 for day-time k night-time pain, respectively). No clinically meaningful changes or other between-group differences were observed in laboratory parameters and adverse events which were evaluated to be related with medication. CONCLUSIONS: In this study, rabeprazole 10 mg produced healing rates and symptom relief equivalent to omeprazole 20 mg at weeks 2 and 4 in patients with active duodenal ulcer and provided a tendency of faster symptom relief than omeprazole 20 mg, although it didn't reach statistical significance. Both the treatments were well tolerated.
Duodenal Ulcer* ; Endoscopy ; Humans ; Korea ; Omeprazole* ; Rabeprazole*

PURPOSE: Recommended dietary allowance of vitamin C was determined on the basis of preventing the scurvy without considerations of the important function of the vitamin C as a first line antioxidant. So we measured the whole blood and plasma vitamin C concentrations of the contemporay healthy elementary school children in Chinju for the establishment of the optimal daily vitamin C requirment in the elementary school children. METHODS: Whole blood and plasma vitamin C concentrations were measured by the 2,4-dinitrophenylhydrazine method in 338 children from the 1st to the 6th grade of one elementary school in Chinju. RESULTS: Whole blood and plasma vitamin C concentrations were 1.36+/-0.34mg/dL and 1.07+/-0.33mg/dL respectively. There existed an close relationship between whole blood and plasma vitamin C concentrations (r=0.77, p=0.0001). Whole blood vitamin C concentration decreased as the age became older (r=-0.22 p=0.0001), but plasma vitamin C concentration did not change. There were no sex differences in the whole blood and plasma vitamin C concentrations except in the 3rd grade (p<0.05). Twenty-three of 338 elementary school children (6.8%) had the plasma vitamin C concentration less than 0.6mg/dL. CONCLUSIONS: We produced the blood and plasma vitamin C concentrations of the contemporay elementary school children in Chinju. These values were not satisfactory in consideration of the importance of the childhood health.
Ascorbic Acid* ; Child* ; Gyeongsangnam-do* ; Humans ; Plasma* ; Recommended Dietary Allowances ; Scurvy ; Sex Characteristics ; Vitamins*

BACKGROUND: Obesity is one of the major risk factors for coronary artery disease. However, the long-term clinical effects of obesity after percutaneus coronary intervention (PCI) in Korean patients with acute myocardial infarction (AMI) have not been sufficiently evaluated. METHODS: A total of 309 patients (mean age 60.5+/-11.3 years, M:F=243:66) that underwent PCI with a diagnosis of AMI between February 2002 and June 2006. Thepatients were divided into two groups according to the body mass index (BMI): group I (n=194; BMI <25 kg/m2; mean age 61.7+/-11.1 years, M:F=151:43) and group II (n=115; BMI> or =25 kg/m2, mean age 58.2+/-11.3 years, M:F=92:23). Clinical characteristics and risk factors, and major adverse cardiac events during a six-month follow-up were compared between patients in the two gropus. RESULTS: The mean age of group I patients was older than that of group II patients (61.7+/-11.1 years vs. 58.6+/-11.5 years, p=0.017). The prevalence of hypertension was higher in group II patients (75/194, 38.7% vs.59/115, 51.3%, p=0.033) and hyperlipidemia was more prevalent in group II patients (75/194, 38.7% vs. 60/115, 52.2%, p=0.024). The levels of total cholesterol (184.3+/-39.9 mg/dL vs. 201.4+/-42.6 mg/dL, p=0.001), triglycerides (121.2+/-61.6 mg/dL vs. 147.1+/-96.2 mg/dL, p=0.005), low-density lipoprotein-cholesterol (120.3+/-35.1 mg/dL vs. 134.1+/-37.8 mg/dL, p=0.002) were lower in group I patients than in group II patients. The restenosis rate on a follow-up coronary angiogram was higher in group II patients (18/69, 26.1%) than in group I patients (14/109, 12.8%, p=0.025). CONCLUSIONS: Obesity is associated with hyperlipidemia and hypertension in patients with AMI. The restenosis rate after PCI was higher in obese AMI patients.
Body Mass Index* ; Cholesterol ; Coronary Artery Disease ; Diagnosis ; Follow-Up Studies ; Humans ; Hyperlipidemias ; Hypertension ; Myocardial Infarction* ; Obesity ; Percutaneous Coronary Intervention* ; Prevalence ; Prognosis ; Risk Factors ; Triglycerides

BACKGROUND/AIMS: The aims of this study were to determine subgoups of functional dyspesia and to evaluate the short-term effect of cisapride in patients with functional dyspepsia in Korea. METHODS: 1025 patients, with a mean age of 42.6 years, with symptoms of functional dyspepsia, were recruited consecutively and upper gastrointestinal symptoms were investigated by interview in 41 hospitals in Korea. In an open, multicenter trial, 1025 patients received Smg of cisapride three times a day (TID) for at least .2 weeks for the treatment of symptoms of functional dyspepsia. When necessary, the dose of cisapride was increased to 10mg TID and the duration of therapy was extended to 4 weeks. RESULTS: The most frequently reported symptoms of functional dyspepsia were epigastric discomfort or fullness (85%), bloating (70%), belching (53%), early satiety (52%) and epigastric pain (46%) retrospectively. Subgroups of functional dyspepsia were as follows; dysmotility-like 73.5%, ulcer-like 39.7%, reflux-like 13.0%, and unspecified dyspepsia 14.0%. However, 33.2% of subjects with functional dyspepsia could be classified into more than one subgroup. Upper gastrointestinal symptoms were decreased to average 50.3% (range; 42.2 to 59.2%) after 2 weeks of cisapride treatment and to 25% (19.2 to 29.9%) after 4 weeks. cisapride therapy resulted in good or excellent improvement in 59.0% of the patients after two weeks, in 75% of patients after 4 weeks. Adverse events were occurred in 52 patients (5.8% of all patients), most commonly, loose stools or diarrhea (3.5%), abdominal pain (1.1%), and dizziness (0.3%). The majority of adverse events was mild and transient in nature and led to premature discontinuation of treatment in 4 patients. CONCLUSIONS: Although the majorities of patients with functional dyspepsia have dysmotility like symptoms in Korea, there is such overlap among the dyspepsia subgroups. Most patients responded well to a short therapeutic trial with cisapride without significant side effects.
Abdominal Pain ; Cisapride* ; Diarrhea ; Dizziness ; Dyspepsia* ; Eructation ; Humans ; Korea* ; Retrospective Studies